Metformin inhibits the development and metastasis of ovarian cancer

Oncology Reports

Volumn 28, Issue 3, 2012, Pages 903-908

  Wu, Buchu ^a   Li, Shu ^a   Sheng, Lili ^a   Zhu, Jing ^a   Gu, Liying ^a   Shen, Haoran ^a   La, Duanduan ^a   Hambly, Brett D ^b   Bao, Shisan ^a,b   Di, Wen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Metastasis; Metformin; Ovarian cancer

Indexed keywords

METFORMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CELL ADHESION; CELL INFILTRATION; CELL INTERACTION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE METASTASIS; LIVER METASTASIS; LUNG METASTASIS; MACROPHAGE; METASTASIS; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; METFORMIN; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865317251     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1890     Document Type: Article

References (21)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Zhang J and Wang B: Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. Gynecol Oncol 103: 199-206, 2006.
3. Gubbels JA, Claussen N, Kapur AK, Connor JP and Patankar MS: The detection, treatment, and biology of epithelial ovarian cancer. J Ovarian Res 3: 8, 2010.
4. Bailey CJ and Turner RC: Metformin. N Engl J Med 334: 574-579, 1996.
5. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR and Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305, 2005.
6. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625, 2009.
7. Cip1. J Mol Signal 3: 18, 2008.
8. Ben Sahra I, Laurent K, Loubat A, et al: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008.
9. Gotlieb WH, Saumet J, Beauchamp MC, et al: In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110: 246-250, 2008.
10. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of endometrial cancer cell proliferation - implications for a novel treatment strategy. Gynecol Oncol 116: 92-98, 2010.
11. Zakikhani M, Dowling R, Fantus IG, Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273, 2006.
12. Buzzai M, Jones RG, Amaravadi RK, et al: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752, 2007.
13. Hirsch HA, Iliopoulos D, Tsichlis PN and Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507-7511, 2009.
14. Shenhua X, Lijuan Q, Hanzhou N, et al: Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res 18: 233-239, 1999.
15. Zhang S, Lin QD and Di W: Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer 16: 522-531, 2006.
16. Bao S, Carr ED, Xu YH and Hunt NH: Gp91(phox) contributes to the development of experimental inflammatory bowel disease. Immunol Cell Biol 89: 853-860, 2011.
17. Xu Y, Hunt NH and Bao S: The role of granulocyte macrophage- colony-stimulating factor in acute intestinal inflammation. Cell Res 18: 1220-1229, 2008.
18. Phoenix KN, Vumbaca F and Claffey KP: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat 113: 101-111, 2009.
19. Brem S, Cotran R and Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48: 347-356, 1972.
20. Jonjic N, Peri G, Bernasconi S, et al: Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 176: 1165-1174, 1992.
21. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.